• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Stanford researchers identify human bladder cancer stem cell

Article

Researchers at the Stanford University School of Medicine, Stanford, CA have identified the first human bladder cancer stem cell and have explained its role in evading the body?s natural defenses.

Researchers at the Stanford University School of Medicine, Stanford, CA have identified the first human bladder cancer stem cell and have explained its role in evading the body’s natural defenses.

"This is first time we’ve found this 'don’t eat me signal' in a stem cell of a solid cancer," said senior study author Irving Weissman, MD. "We’re now moving as fast as we can to look at other tumors to see if this is a universal strategy of all or most cancer stem cells."

Detecting and tracking the stem cells may be one way to monitor tumor status, researchers say, and targeting the cells to be destroyed may be a means to remove the cancer.

To find a subpopulation of human bladder cancer cells with stem cell qualities, the team used breast cancer stem cell markers. When transplanted into mice that had weakened immune systems, the cells formed tumors. Researchers observed which genes were more highly expressed in the cells than in other bladder cancer cells from the same tumor.

Findings showed most, but not all, noninvasive bladder cancers indicated lower levels of the genes than invasive cancers did. Further, the anomalous noninvasive cancers with higher levels of gene expression were more aggressive: 80% recurred within 25 months of diagnosis; only 20% of non-expressive tumors did.

One cell was discovered that encodes a cell-surface molecule called CD47. CD47 prevents leukemia cells from being consumed by macrophages by binding to a molecule on the macrophage surface. Preventing contact with an antibody specific to CD47 enables the macrophages to consume the leukemia cells.

The study is published in the Aug. 3 Proceedings of the National Academy of Sciences.

Related Videos
Gary D. Steinberg, MD, an expert on bladder cancer
Akhil Das, MD, FACS, answers a question during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Woman talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.